nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—BCHE—Cisplatin—bone cancer	0.331	0.473	CbGbCtD
Procainamide—SLC22A2—Cisplatin—bone cancer	0.315	0.451	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—bone cancer	0.053	0.0758	CbGbCtD
Procainamide—Sunitinib—CHEK2—bone cancer	0.0155	0.396	CrCbGaD
Procainamide—Sunitinib—KIT—bone cancer	0.00819	0.209	CrCbGaD
Procainamide—Lidocaine—EGFR—bone cancer	0.00759	0.193	CrCbGaD
Procainamide—Pericarditis—Methotrexate—bone cancer	0.00447	0.0279	CcSEcCtD
Procainamide—Pericarditis—Epirubicin—bone cancer	0.00418	0.0261	CcSEcCtD
Procainamide—Pericarditis—Doxorubicin—bone cancer	0.00387	0.0241	CcSEcCtD
Procainamide—Body temperature increased—Carboplatin—bone cancer	0.00338	0.0211	CcSEcCtD
Procainamide—Probenecid—CYP3A4—bone cancer	0.00288	0.0735	CrCbGaD
Procainamide—Haemolytic anaemia—Cisplatin—bone cancer	0.00283	0.0177	CcSEcCtD
Procainamide—Lidocaine—CYP3A4—bone cancer	0.00277	0.0706	CrCbGaD
Procainamide—Hepatomegaly—Epirubicin—bone cancer	0.00255	0.0159	CcSEcCtD
Procainamide—Pleural effusion—Methotrexate—bone cancer	0.00252	0.0157	CcSEcCtD
Procainamide—Hepatomegaly—Doxorubicin—bone cancer	0.00236	0.0147	CcSEcCtD
Procainamide—Pleural effusion—Epirubicin—bone cancer	0.00236	0.0147	CcSEcCtD
Procainamide—Sunitinib—CYP3A4—bone cancer	0.00227	0.0578	CrCbGaD
Procainamide—Pleural effusion—Doxorubicin—bone cancer	0.00218	0.0136	CcSEcCtD
Procainamide—Abdominal discomfort—Cisplatin—bone cancer	0.00212	0.0132	CcSEcCtD
Procainamide—Oliguria—Methotrexate—bone cancer	0.0021	0.0131	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—bone cancer	0.00204	0.0127	CcSEcCtD
Procainamide—Vasculitis—Methotrexate—bone cancer	0.00198	0.0123	CcSEcCtD
Procainamide—Oliguria—Epirubicin—bone cancer	0.00196	0.0122	CcSEcCtD
Procainamide—Renal failure—Cisplatin—bone cancer	0.00194	0.0121	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—bone cancer	0.00181	0.0113	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—bone cancer	0.00181	0.0113	CcSEcCtD
Procainamide—Bradycardia—Cisplatin—bone cancer	0.0018	0.0112	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—bone cancer	0.00167	0.0104	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—bone cancer	0.00164	0.0103	CcSEcCtD
Procainamide—Flushing—Cisplatin—bone cancer	0.00164	0.0102	CcSEcCtD
Procainamide—Cardiac disorder—Cisplatin—bone cancer	0.00164	0.0102	CcSEcCtD
Procainamide—Hepatic failure—Methotrexate—bone cancer	0.00156	0.00974	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—bone cancer	0.00152	0.00949	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—bone cancer	0.00146	0.00911	CcSEcCtD
Procainamide—Lethargy—Methotrexate—bone cancer	0.00143	0.00893	CcSEcCtD
Procainamide—Ill-defined disorder—Cisplatin—bone cancer	0.00143	0.00891	CcSEcCtD
Procainamide—Malaise—Cisplatin—bone cancer	0.00139	0.00866	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—bone cancer	0.00138	0.0086	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—bone cancer	0.00135	0.00843	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—bone cancer	0.00134	0.00839	CcSEcCtD
Procainamide—Lethargy—Epirubicin—bone cancer	0.00134	0.00836	CcSEcCtD
Procainamide—Convulsion—Cisplatin—bone cancer	0.00133	0.00832	CcSEcCtD
Procainamide—Myalgia—Cisplatin—bone cancer	0.00131	0.00817	CcSEcCtD
Procainamide—Discomfort—Cisplatin—bone cancer	0.00129	0.00808	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—bone cancer	0.00128	0.00796	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—bone cancer	0.00125	0.00779	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—bone cancer	0.00124	0.00776	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—bone cancer	0.00124	0.00773	CcSEcCtD
Procainamide—Thrombocytopenia—Cisplatin—bone cancer	0.00123	0.00767	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—bone cancer	0.0012	0.00749	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—bone cancer	0.0012	0.00748	CcSEcCtD
Procainamide—Anorexia—Cisplatin—bone cancer	0.0012	0.00747	CcSEcCtD
Procainamide—Hypotension—Cisplatin—bone cancer	0.00117	0.00732	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—bone cancer	0.00116	0.00725	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—bone cancer	0.00115	0.0072	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00114	0.00714	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—bone cancer	0.00113	0.00707	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—bone cancer	0.00112	0.00701	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—bone cancer	0.00111	0.00692	CcSEcCtD
Procainamide—Decreased appetite—Cisplatin—bone cancer	0.00109	0.00681	CcSEcCtD
Procainamide—Depression—Methotrexate—bone cancer	0.00108	0.00672	CcSEcCtD
Procainamide—Renal failure—Methotrexate—bone cancer	0.00106	0.00663	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—bone cancer	0.00106	0.00662	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—bone cancer	0.00104	0.00648	CcSEcCtD
Procainamide—Feeling abnormal—Cisplatin—bone cancer	0.00103	0.00646	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—bone cancer	0.00101	0.00629	CcSEcCtD
Procainamide—Renal failure—Epirubicin—bone cancer	0.000994	0.0062	CcSEcCtD
Procainamide—Body temperature increased—Cisplatin—bone cancer	0.000993	0.00619	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—bone cancer	0.000981	0.00612	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—bone cancer	0.000943	0.00589	CcSEcCtD
Procainamide—Hypersensitivity—Cisplatin—bone cancer	0.000925	0.00577	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—bone cancer	0.000924	0.00577	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—bone cancer	0.00092	0.00574	CcSEcCtD
Procainamide—Asthenia—Cisplatin—bone cancer	0.000901	0.00562	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—bone cancer	0.0009	0.00562	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—bone cancer	0.000873	0.00545	CcSEcCtD
Procainamide—Chills—Methotrexate—bone cancer	0.00087	0.00543	CcSEcCtD
Procainamide—Diarrhoea—Cisplatin—bone cancer	0.000859	0.00536	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—bone cancer	0.000855	0.00534	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—bone cancer	0.000842	0.00526	CcSEcCtD
Procainamide—Flushing—Epirubicin—bone cancer	0.000842	0.00526	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—bone cancer	0.000827	0.00516	CcSEcCtD
Procainamide—Chills—Epirubicin—bone cancer	0.000814	0.00508	CcSEcCtD
Procainamide—Vomiting—Cisplatin—bone cancer	0.000798	0.00498	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—bone cancer	0.000783	0.00489	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—bone cancer	0.000779	0.00486	CcSEcCtD
Procainamide—Flushing—Doxorubicin—bone cancer	0.000779	0.00486	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—bone cancer	0.000774	0.00483	CcSEcCtD
Procainamide—Malaise—Methotrexate—bone cancer	0.000761	0.00475	CcSEcCtD
Procainamide—Chills—Doxorubicin—bone cancer	0.000754	0.0047	CcSEcCtD
Procainamide—Nausea—Cisplatin—bone cancer	0.000746	0.00465	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—bone cancer	0.000733	0.00458	CcSEcCtD
Procainamide—Convulsion—Methotrexate—bone cancer	0.000731	0.00457	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—bone cancer	0.000719	0.00449	CcSEcCtD
Procainamide—Myalgia—Methotrexate—bone cancer	0.000719	0.00449	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—bone cancer	0.000716	0.00447	CcSEcCtD
Procainamide—Malaise—Epirubicin—bone cancer	0.000712	0.00445	CcSEcCtD
Procainamide—Discomfort—Methotrexate—bone cancer	0.00071	0.00443	CcSEcCtD
Procainamide—Confusional state—Methotrexate—bone cancer	0.000695	0.00434	CcSEcCtD
Procainamide—Convulsion—Epirubicin—bone cancer	0.000685	0.00427	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—bone cancer	0.000678	0.00423	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—bone cancer	0.000675	0.00421	CcSEcCtD
Procainamide—Myalgia—Epirubicin—bone cancer	0.000673	0.0042	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—bone cancer	0.000673	0.0042	CcSEcCtD
Procainamide—Discomfort—Epirubicin—bone cancer	0.000665	0.00415	CcSEcCtD
Procainamide—Malaise—Doxorubicin—bone cancer	0.000659	0.00411	CcSEcCtD
Procainamide—Anorexia—Methotrexate—bone cancer	0.000657	0.0041	CcSEcCtD
Procainamide—Confusional state—Epirubicin—bone cancer	0.00065	0.00406	CcSEcCtD
Procainamide—Hypotension—Methotrexate—bone cancer	0.000644	0.00402	CcSEcCtD
Procainamide—Shock—Epirubicin—bone cancer	0.000634	0.00396	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—bone cancer	0.000633	0.00395	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—bone cancer	0.000631	0.00394	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000628	0.00392	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—bone cancer	0.000622	0.00388	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—bone cancer	0.000622	0.00388	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—bone cancer	0.000615	0.00384	CcSEcCtD
Procainamide—Anorexia—Epirubicin—bone cancer	0.000615	0.00384	CcSEcCtD
Procainamide—Hypotension—Epirubicin—bone cancer	0.000603	0.00376	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—bone cancer	0.000602	0.00375	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—bone cancer	0.000599	0.00374	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000587	0.00367	CcSEcCtD
Procainamide—Shock—Doxorubicin—bone cancer	0.000587	0.00366	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—bone cancer	0.000584	0.00365	CcSEcCtD
Procainamide—CHRM2—GPCRs, Other—SMO—bone cancer	0.000573	0.00566	CbGpPWpGaD
Procainamide—Anorexia—Doxorubicin—bone cancer	0.000569	0.00355	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—bone cancer	0.000568	0.00354	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—bone cancer	0.000563	0.00352	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—bone cancer	0.000561	0.0035	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—bone cancer	0.000558	0.00348	CcSEcCtD
Procainamide—DNMT1—Gene Expression—FUS—bone cancer	0.000555	0.00548	CbGpPWpGaD
Procainamide—SCN8A—L1CAM interactions—EGFR—bone cancer	0.000551	0.00544	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000549	0.00542	CbGpPWpGaD
Procainamide—Urticaria—Methotrexate—bone cancer	0.000547	0.00342	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—bone cancer	0.000545	0.0034	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—bone cancer	0.000545	0.0034	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000544	0.00339	CcSEcCtD
Procainamide—SLC22A4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000543	0.00536	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—MOGS—bone cancer	0.000535	0.00528	CbGpPWpGaD
Procainamide—ACHE—ATF-2 transcription factor network—RB1—bone cancer	0.000534	0.00527	CbGpPWpGaD
Procainamide—Feeling abnormal—Epirubicin—bone cancer	0.000531	0.00332	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—bone cancer	0.000527	0.00329	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—bone cancer	0.000519	0.00324	CcSEcCtD
Procainamide—Urticaria—Epirubicin—bone cancer	0.000512	0.0032	CcSEcCtD
Procainamide—ACHE—ATF-2 transcription factor network—MMP2—bone cancer	0.000512	0.00506	CbGpPWpGaD
Procainamide—Abdominal pain—Epirubicin—bone cancer	0.00051	0.00318	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—bone cancer	0.00051	0.00318	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—bone cancer	0.000508	0.00317	CcSEcCtD
Procainamide—SCN7A—Axon guidance—MET—bone cancer	0.000504	0.00498	CbGpPWpGaD
Procainamide—Asthenia—Methotrexate—bone cancer	0.000494	0.00309	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—bone cancer	0.000492	0.00307	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000488	0.00304	CcSEcCtD
Procainamide—Pruritus—Methotrexate—bone cancer	0.000487	0.00304	CcSEcCtD
Procainamide—BCHE—Metabolism of proteins—MOGS—bone cancer	0.000477	0.00471	CbGpPWpGaD
Procainamide—Hypersensitivity—Epirubicin—bone cancer	0.000475	0.00296	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—bone cancer	0.000474	0.00296	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—bone cancer	0.000472	0.00294	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—bone cancer	0.000472	0.00294	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—bone cancer	0.000471	0.00294	CcSEcCtD
Procainamide—SLC22A4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000469	0.00463	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000466	0.00461	CbGpPWpGaD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000465	0.00459	CbGpPWpGaD
Procainamide—Asthenia—Epirubicin—bone cancer	0.000463	0.00289	CcSEcCtD
Procainamide—Pruritus—Epirubicin—bone cancer	0.000456	0.00285	CcSEcCtD
Procainamide—Dizziness—Methotrexate—bone cancer	0.000456	0.00284	CcSEcCtD
Procainamide—SCN11A—Axon guidance—MET—bone cancer	0.000449	0.00443	CbGpPWpGaD
Procainamide—SCN9A—L1CAM interactions—EGFR—bone cancer	0.000445	0.0044	CbGpPWpGaD
Procainamide—Diarrhoea—Epirubicin—bone cancer	0.000441	0.00275	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—bone cancer	0.00044	0.00274	CcSEcCtD
Procainamide—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.000439	0.00434	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.000439	0.00434	CbGpPWpGaD
Procainamide—Vomiting—Methotrexate—bone cancer	0.000438	0.00273	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—bone cancer	0.000428	0.00267	CcSEcCtD
Procainamide—Dizziness—Epirubicin—bone cancer	0.000426	0.00266	CcSEcCtD
Procainamide—SCN3A—L1CAM interactions—EGFR—bone cancer	0.000426	0.00421	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000425	0.00419	CbGpPWpGaD
Procainamide—Pruritus—Doxorubicin—bone cancer	0.000422	0.00263	CcSEcCtD
Procainamide—SCN7A—Axon guidance—MMP2—bone cancer	0.00042	0.00415	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—MET—bone cancer	0.000411	0.00406	CbGpPWpGaD
Procainamide—Vomiting—Epirubicin—bone cancer	0.00041	0.00256	CcSEcCtD
Procainamide—SLC22A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00041	0.00405	CbGpPWpGaD
Procainamide—Nausea—Methotrexate—bone cancer	0.000409	0.00255	CcSEcCtD
Procainamide—SCN4A—L1CAM interactions—EGFR—bone cancer	0.000409	0.00404	CbGpPWpGaD
Procainamide—SCN2A—L1CAM interactions—EGFR—bone cancer	0.000409	0.00404	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000408	0.00403	CbGpPWpGaD
Procainamide—Diarrhoea—Doxorubicin—bone cancer	0.000408	0.00255	CcSEcCtD
Procainamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000401	0.00396	CbGpPWpGaD
Procainamide—ACHE—ATF-2 transcription factor network—JUN—bone cancer	0.000395	0.00391	CbGpPWpGaD
Procainamide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000395	0.0039	CbGpPWpGaD
Procainamide—SCN1A—L1CAM interactions—EGFR—bone cancer	0.000395	0.0039	CbGpPWpGaD
Procainamide—SCN10A—L1CAM interactions—EGFR—bone cancer	0.000395	0.0039	CbGpPWpGaD
Procainamide—Dizziness—Doxorubicin—bone cancer	0.000395	0.00246	CcSEcCtD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000387	0.00382	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—NR1I2—bone cancer	0.000385	0.0038	CbGpPWpGaD
Procainamide—Nausea—Epirubicin—bone cancer	0.000383	0.00239	CcSEcCtD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000382	0.00377	CbGpPWpGaD
Procainamide—Vomiting—Doxorubicin—bone cancer	0.000379	0.00237	CcSEcCtD
Procainamide—SCN11A—Axon guidance—MMP2—bone cancer	0.000375	0.0037	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—CDK4—bone cancer	0.00036	0.00355	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MET—bone cancer	0.00036	0.00355	CbGpPWpGaD
Procainamide—Nausea—Doxorubicin—bone cancer	0.000354	0.00221	CcSEcCtD
Procainamide—SLC22A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000354	0.00349	CbGpPWpGaD
Procainamide—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000354	0.00349	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000352	0.00348	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—MMP2—bone cancer	0.000343	0.00338	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MET—bone cancer	0.000332	0.00328	CbGpPWpGaD
Procainamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000325	0.00321	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000323	0.00319	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MET—bone cancer	0.00032	0.00316	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—CDK4—bone cancer	0.00032	0.00316	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NDUFA12—bone cancer	0.00032	0.00316	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MET—bone cancer	0.000318	0.00314	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—MMP9—bone cancer	0.000316	0.00312	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MET—bone cancer	0.000305	0.00301	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MET—bone cancer	0.000305	0.00301	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MMP2—bone cancer	0.0003	0.00296	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MET—bone cancer	0.000294	0.00291	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MET—bone cancer	0.000294	0.00291	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—CDK4—bone cancer	0.000293	0.00289	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MET—bone cancer	0.000293	0.00289	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—TUBB4B—bone cancer	0.000293	0.00289	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—EIF2S1—bone cancer	0.000284	0.00281	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—MMP9—bone cancer	0.000282	0.00278	CbGpPWpGaD
Procainamide—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000277	0.00274	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MMP2—bone cancer	0.000277	0.00274	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MMP2—bone cancer	0.000267	0.00264	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.000266	0.00263	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NT5C3A—bone cancer	0.000265	0.00262	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MMP2—bone cancer	0.000265	0.00262	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—TUBB4B—bone cancer	0.000261	0.00258	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—MMP9—bone cancer	0.000258	0.00254	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000257	0.00254	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—EGFR—bone cancer	0.000255	0.00252	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MMP2—bone cancer	0.000255	0.00251	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MMP2—bone cancer	0.000255	0.00251	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—TUBB2A—bone cancer	0.000253	0.0025	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NDUFA12—bone cancer	0.000252	0.00249	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—EZH2—bone cancer	0.000247	0.00244	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MMP2—bone cancer	0.000246	0.00242	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MMP2—bone cancer	0.000246	0.00242	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MMP2—bone cancer	0.000244	0.00241	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00024	0.00237	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000239	0.00236	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000239	0.00236	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—CDK4—bone cancer	0.000237	0.00234	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MET—bone cancer	0.000237	0.00234	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—GRM1—bone cancer	0.000231	0.00228	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—EGFR—bone cancer	0.000228	0.00225	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MET—bone cancer	0.000227	0.00224	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—CDK4—bone cancer	0.000227	0.00224	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—TUBB2A—bone cancer	0.000226	0.00223	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MMP9—bone cancer	0.000225	0.00223	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NDUFA12—bone cancer	0.000225	0.00222	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000222	0.00219	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—CDK4—bone cancer	0.000218	0.00215	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MET—bone cancer	0.000218	0.00215	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MET—bone cancer	0.000218	0.00215	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—CDK4—bone cancer	0.000218	0.00215	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MET—bone cancer	0.00021	0.00207	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MET—bone cancer	0.00021	0.00207	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—CDK4—bone cancer	0.00021	0.00207	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—CDK4—bone cancer	0.00021	0.00207	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NT5C3A—bone cancer	0.000209	0.00206	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MMP9—bone cancer	0.000208	0.00206	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—EGFR—bone cancer	0.000208	0.00205	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MET—bone cancer	0.000207	0.00204	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000207	0.00204	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—BRAF—bone cancer	0.000204	0.00202	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MMP9—bone cancer	0.000201	0.00198	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NDUFA12—bone cancer	0.000201	0.00198	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MMP9—bone cancer	0.000199	0.00197	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MMP2—bone cancer	0.000198	0.00195	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MMP9—bone cancer	0.000191	0.00189	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MMP9—bone cancer	0.000191	0.00189	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MMP2—bone cancer	0.000189	0.00187	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NDUFA12—bone cancer	0.000187	0.00185	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NT5C3A—bone cancer	0.000186	0.00184	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MMP9—bone cancer	0.000185	0.00182	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MMP9—bone cancer	0.000185	0.00182	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MMP9—bone cancer	0.000184	0.00181	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—BRAF—bone cancer	0.000182	0.0018	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—EGFR—bone cancer	0.000182	0.0018	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MMP2—bone cancer	0.000182	0.00179	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MMP2—bone cancer	0.000182	0.00179	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000178	0.00176	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—EIF2S1—bone cancer	0.000176	0.00174	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000176	0.00174	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MMP2—bone cancer	0.000175	0.00173	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MMP2—bone cancer	0.000175	0.00173	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MMP2—bone cancer	0.000173	0.0017	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000173	0.0017	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000171	0.00169	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—MDM2—bone cancer	0.000171	0.00169	CbGpPWpGaD
Procainamide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.00017	0.00168	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—EGFR—bone cancer	0.000168	0.00166	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NT5C3A—bone cancer	0.000166	0.00164	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000163	0.00161	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—SMO—bone cancer	0.000163	0.00161	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—EGFR—bone cancer	0.000162	0.0016	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—EGFR—bone cancer	0.000161	0.00159	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—EIF2S1—bone cancer	0.000157	0.00155	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—BRAF—bone cancer	0.000157	0.00155	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NT5C3A—bone cancer	0.000155	0.00153	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—EGFR—bone cancer	0.000155	0.00153	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—EGFR—bone cancer	0.000155	0.00153	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000155	0.00153	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—MDM2—bone cancer	0.000153	0.00151	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000152	0.0015	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—RGS1—bone cancer	0.00015	0.00148	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GRM4—bone cancer	0.00015	0.00148	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—EGFR—bone cancer	0.000149	0.00147	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—EGFR—bone cancer	0.000149	0.00147	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MMP9—bone cancer	0.000149	0.00147	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—EGFR—bone cancer	0.000148	0.00147	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CDK4—bone cancer	0.000148	0.00146	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MET—bone cancer	0.000148	0.00146	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000148	0.00146	CbGpPWpGaD
Procainamide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000146	0.00144	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MMP9—bone cancer	0.000142	0.0014	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—BRAF—bone cancer	0.00014	0.00138	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MMP9—bone cancer	0.000137	0.00135	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MMP9—bone cancer	0.000137	0.00135	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—RGS1—bone cancer	0.000137	0.00135	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GRM4—bone cancer	0.000137	0.00135	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000137	0.00135	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MMP9—bone cancer	0.000132	0.0013	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MMP9—bone cancer	0.000132	0.0013	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—MDM2—bone cancer	0.000131	0.0013	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GRM1—bone cancer	0.00013	0.00129	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MMP9—bone cancer	0.00013	0.00128	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000127	0.00126	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—BRAF—bone cancer	0.000125	0.00123	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000123	0.00122	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP2—bone cancer	0.000123	0.00122	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000121	0.0012	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—EGFR—bone cancer	0.00012	0.00119	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GRM1—bone cancer	0.000118	0.00117	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—MDM2—bone cancer	0.000117	0.00116	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—BRAF—bone cancer	0.000116	0.00115	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ENO2—bone cancer	0.000116	0.00115	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—EGFR—bone cancer	0.000115	0.00113	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—EGFR—bone cancer	0.00011	0.00109	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—EGFR—bone cancer	0.00011	0.00109	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—DHFR—bone cancer	0.000108	0.00106	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—EGFR—bone cancer	0.000106	0.00105	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—EGFR—bone cancer	0.000106	0.00105	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—EGFR—bone cancer	0.000105	0.00104	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—MDM2—bone cancer	0.000105	0.00103	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000103	0.00102	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000102	0.00101	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GNA11—bone cancer	0.000101	0.000995	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000101	0.000994	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—MDM2—bone cancer	9.75e-05	0.000963	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—bone cancer	9.26e-05	0.000914	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ENO2—bone cancer	9.15e-05	0.000904	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CYP3A4—bone cancer	9.14e-05	0.000902	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NT5C3A—bone cancer	8.57e-05	0.000846	CbGpPWpGaD
Procainamide—ACHE—Metabolism—DHFR—bone cancer	8.49e-05	0.000838	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GNA11—bone cancer	8.4e-05	0.00083	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SMO—bone cancer	8.34e-05	0.000824	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ENO2—bone cancer	8.16e-05	0.000806	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GRM4—bone cancer	8.07e-05	0.000797	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RGS1—bone cancer	8.07e-05	0.000797	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GNA11—bone cancer	7.93e-05	0.000783	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GSTP1—bone cancer	7.81e-05	0.000772	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GNA11—bone cancer	7.63e-05	0.000753	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL3—bone cancer	7.62e-05	0.000752	CbGpPWpGaD
Procainamide—BCHE—Metabolism—DHFR—bone cancer	7.57e-05	0.000748	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EGFR—bone cancer	7.48e-05	0.000739	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ENO2—bone cancer	7.29e-05	0.00072	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—MMP2—bone cancer	7.22e-05	0.000713	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CYP3A4—bone cancer	7.19e-05	0.00071	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.16e-05	0.000707	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GNA11—bone cancer	7.08e-05	0.000699	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GRM1—bone cancer	6.99e-05	0.000691	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL3—bone cancer	6.92e-05	0.000683	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ENO2—bone cancer	6.8e-05	0.000671	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—DHFR—bone cancer	6.76e-05	0.000668	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—MMP2—bone cancer	6.44e-05	0.000636	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CYP3A4—bone cancer	6.42e-05	0.000634	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.38e-05	0.00063	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GNA11—bone cancer	6.32e-05	0.000624	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—DHFR—bone cancer	6.3e-05	0.000623	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GSTP1—bone cancer	6.15e-05	0.000607	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GNA11—bone cancer	5.89e-05	0.000582	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYP3A4—bone cancer	5.73e-05	0.000566	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GSTP1—bone cancer	5.49e-05	0.000542	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYP3A4—bone cancer	5.34e-05	0.000527	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMO—bone cancer	4.93e-05	0.000487	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GSTP1—bone cancer	4.9e-05	0.000484	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GSTP1—bone cancer	4.57e-05	0.000451	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GNA11—bone cancer	4.51e-05	0.000445	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ATF1—bone cancer	4.19e-05	0.000414	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL3—bone cancer	4.09e-05	0.000403	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—bone cancer	4.05e-05	0.0004	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—bone cancer	3.75e-05	0.000371	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFBR2—bone cancer	3.49e-05	0.000345	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—DHFR—bone cancer	3.48e-05	0.000344	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF1R—bone cancer	3.29e-05	0.000325	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GNA11—bone cancer	3.25e-05	0.000321	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—bone cancer	3.19e-05	0.000315	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP3A4—bone cancer	2.95e-05	0.000291	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—bone cancer	2.84e-05	0.000281	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—bone cancer	2.54e-05	0.000251	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GSTP1—bone cancer	2.52e-05	0.000249	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KIT—bone cancer	2.38e-05	0.000235	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—bone cancer	2.37e-05	0.000234	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BRAF—bone cancer	2.24e-05	0.000221	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—EGFR—bone cancer	2.17e-05	0.000215	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MDM2—bone cancer	1.88e-05	0.000185	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JUN—bone cancer	1.63e-05	0.000161	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—bone cancer	1.59e-05	0.000157	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—bone cancer	1.31e-05	0.000129	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGFR—bone cancer	1.28e-05	0.000127	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—bone cancer	1.08e-05	0.000106	CbGpPWpGaD
